Basit öğe kaydını göster

Alisporivir (ALV) plus Peg-interferon/Ribavirin (PR) achieves high on-treatment undetectable HCV RNA levels among the most difficult to treat HCV G1 patients. Results of a planned treatment week 24 interim analysis of a randomized, double blind, placebo controlled trial (FUNDAMENTAL study)

dc.contributor.authorMazzella, Giuseppe
dc.contributor.authorDavis, Gary L.
dc.contributor.authorKao, Jia-Horng
dc.contributor.authorAlberti, Alfredo
dc.contributor.authorChuang, Wan-Long
dc.contributor.authorFlisiak, Robert
dc.contributor.authorHorban, Andrzej
dc.contributor.authorGoeser, Tobias
dc.contributor.authorCalistru, Petre I.
dc.contributor.authorButi, Maria
dc.contributor.authorStreinu-Cercel, Adrian
dc.contributor.authorDesmond, Paul V.
dc.contributor.authorHorvath, Gabor
dc.contributor.authorPol, Stanislas
dc.contributor.authorDusheiko, Geoffrey M.
dc.contributor.authorGong, Yankun
dc.contributor.authorOrsenigo, Roberto
dc.contributor.authorAvila, Claudio
dc.contributor.authorTabak, Fehmi
dc.date.accessioned2021-03-06T08:14:10Z
dc.date.available2021-03-06T08:14:10Z
dc.date.issued2012
dc.identifier.citationDavis G. L. , Kao J., Alberti A., Chuang W., Flisiak R., Mazzella G., Horban A., Goeser T., Calistru P. I. , Buti M., et al., "Alisporivir (ALV) plus Peg-interferon/Ribavirin (PR) achieves high on-treatment undetectable HCV RNA levels among the most difficult to treat HCV G1 patients. Results of a planned treatment week 24 interim analysis of a randomized, double blind, placebo controlled trial (FUNDAMENTAL study)", HEPATOLOGY, cilt.56, ss.1531, 2012
dc.identifier.issn0270-9139
dc.identifier.othervv_1032021
dc.identifier.otherav_dfe75eb5-3984-4365-9afe-a3b87802c10f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/147497
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectGastroenteroloji-(Hepatoloji)
dc.subjectSağlık Bilimleri
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.subjectTıp
dc.titleAlisporivir (ALV) plus Peg-interferon/Ribavirin (PR) achieves high on-treatment undetectable HCV RNA levels among the most difficult to treat HCV G1 patients. Results of a planned treatment week 24 interim analysis of a randomized, double blind, placebo controlled trial (FUNDAMENTAL study)
dc.typeMakale
dc.relation.journalHEPATOLOGY
dc.contributor.departmentBaylor Health Care System , ,
dc.identifier.volume56
dc.identifier.issue6
dc.identifier.startpage1531
dc.identifier.endpage1531
dc.contributor.firstauthorID207336


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster